LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

Search

AstraZeneca PLC ADR

Chiusa

72.79 2.77

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

72.77

Massimo

73.19

Metriche Chiave

By Trading Economics

Entrata

1.7B

3.4B

Vendite

-1.3B

14B

P/E

Media del settore

28.277

53.54

EPS

0.934

Rendimento da dividendi

2.2

Margine di Profitto

25.037

Dipendenti

94,300

EBITDA

610M

5B

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+19.65% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

2.20%

2.44%

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

1.5B

218B

Apertura precedente

70.02

Chiusura precedente

72.79

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

AstraZeneca PLC ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

12 mag 2025, 09:36 UTC

I principali Market Mover

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

29 apr 2025, 10:14 UTC

Utili

Correction to AstraZeneca Update

29 apr 2025, 09:15 UTC

Utili

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China -- 2nd Update

29 apr 2025, 08:12 UTC

Utili

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China -- Update

29 apr 2025, 06:32 UTC

Utili

AstraZeneca Sales, Earnings Rise

24 mar 2025, 03:15 UTC

I principali Market Mover

Harbour BioMed Shares Soar on News of AstraZeneca Collaboration

28 mag 2025, 18:09 UTC

Utili

Heart Disease Could Be a Goner When These New -2-

28 mag 2025, 18:09 UTC

Utili

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

20 mag 2025, 06:09 UTC

Acquisizioni, Fusioni, Takeovers

AstraZeneca Completes Acquisition of EsoBiotec

12 mag 2025, 12:07 UTC

Discorsi di Mercato

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12 mag 2025, 07:20 UTC

Discorsi di Mercato

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

8 mag 2025, 15:20 UTC

Utili

Trump Announces U.S.-U.K. Trade Deal. Most Tariffs Aren't Coming Down. -- Barrons.com

29 apr 2025, 13:09 UTC

Discorsi di Mercato
Utili

AstraZeneca's Oncology Miss Doesn't Dent Positive Outlook -- Market Talk

29 apr 2025, 08:04 UTC

Discorsi di Mercato
Utili

AstraZeneca's Results Provide a Mixed Picture -- Market Talk

29 apr 2025, 06:05 UTC

Utili

AstraZeneca 1Q Core EPS $2.49

29 apr 2025, 06:04 UTC

Utili

AstraZeneca 1Q Net Pft $2.92B

29 apr 2025, 06:02 UTC

Utili

AstraZeneca: Committed to Further Invest and Grow in the U.S.

29 apr 2025, 06:00 UTC

Utili

AstraZeneca 1Q Core EPS Consensus Was $2.27

29 apr 2025, 06:00 UTC

Utili

AstraZeneca 1Q Revenue Consensus Was $13.80B

29 apr 2025, 06:00 UTC

Utili

AstraZeneca Backs 2025 View

29 apr 2025, 06:00 UTC

Utili

AstraZeneca PLC 1Q EPS $1.87

29 apr 2025, 06:00 UTC

Utili

AstraZeneca PLC 1Q Rev $13.59B

29 apr 2025, 06:00 UTC

Utili

AstraZeneca PLC 1Q Oper Pft $3.67B

29 apr 2025, 06:00 UTC

Utili

AstraZeneca PLC 1Q Pretax Pft $3.4B

15 apr 2025, 09:55 UTC

Discorsi di Mercato

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

9 apr 2025, 07:23 UTC

Discorsi di Mercato

Pharma Stocks Tumble After Trump Floats Tariffs on Industry -- Market Talk

3 apr 2025, 08:41 UTC

Discorsi di Mercato

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

3 apr 2025, 08:36 UTC

Discorsi di Mercato

U.K. Pharma to Have Some Share-Price Volatility But Long-Term Outlook Remains Intact -- Market Talk

3 apr 2025, 07:51 UTC

Discorsi di Mercato

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

31 mar 2025, 09:31 UTC

Azioni calde

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

Confronto tra pari

Modifica del prezzo

AstraZeneca PLC ADR Previsione

Obiettivo di Prezzo

By TipRanks

19.65% in crescita

Previsioni per 12 mesi

Media 87.14 USD  19.65%

Alto 97 USD

Basso 75 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per AstraZeneca PLC ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

7 ratings

7

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

N/A / 69.55Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Strong Bearish Evidence

A lungo termine

Weak Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo AstraZeneca PLC ADR

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.